← All trials
NCT03755778
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 29, 2018
- Primary completion
- Jan 21, 2019
- Completion date
- Jan 27, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 72
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Enanta PharmaceuticalsLead sponsor
- Enanta PharmaceuticalsStudy director
- Pharmaceutical Research Associates, Inc. (PRA)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.